From the Wallenberg Laboratory, Göteborg
University, S-413 45 Göteborg, Sweden, the ¶ Institute of
Laboratory Medicine, Department of Clinical Chemistry, Lund University
Hospital, 221 85 Lund, Sweden, the
Department of Internal
Medicine, Helsingborg Hospital, 251 87 Helsingborg, Sweden, and
the ** Gladstone Institute of Cardiovascular Disease, Cardiovascular
Research Institute, and Department of Pathology, University of
California, San Francisco, CA 94141-9100
Received for publication, September 28, 2000, and in revised form, December 11, 2000
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Familial defective apolipoprotein B100 (FDB) is a
genetic disorder in which low density lipoproteins (LDL) bind
defectively to the LDL receptor, resulting in hypercholesterolemia and
premature atherosclerosis. FDB is caused by a mutation (R3500Q) that
changes the conformation of apolipoprotein (apo) B100 near the
receptor-binding site. We previously showed that arginine, not simply a
positive charge, at residue 3500 is essential for normal receptor
binding and that the carboxyl terminus of apoB100 is necessary for
mutations affecting arginine 3500 to disrupt LDL receptor
binding. Thus, normal receptor binding involves an interaction between
arginine 3500 and tryptophan 4369 in the carboxyl tail of apoB100.
W4369Y LDL and R3500Q LDL isolated from transgenic mice had identically defective LDL binding and a higher affinity for the monoclonal antibody
MB47, which has an epitope flanking residue 3500. We conclude that
arginine 3500 interacts with tryptophan 4369 and facilitates the
conformation of apoB100 required for normal receptor binding of LDL.
From our findings, we developed a model that explains how the carboxyl
terminus of apoB100 interacts with the backbone of apoB100 that enwraps
the LDL particle. Our model also explains how all known
ligand-defective mutations in apoB100, including a newly discovered
R3480W mutation in apoB100, cause defective receptor binding.
The interaction between low density lipoprotein
(LDL)1 and the LDL receptor
is fundamental for the regulation of plasma cholesterol in humans (1).
The sole protein component of LDL is apolipoprotein (apo) B100, which
serves as the ligand for the LDL receptor (2). We recently identified
the sequence in apoB100 that interacts with the LDL receptor (3).
However, the ability of apoB100 to interact with the LDL receptor
depends not only on sequence, but also on conformation, because apoB100
binds to the LDL receptor only after the hydrolysis of
triglyceride-rich very low density lipoproteins (VLDL) to smaller
cholesterol-rich LDL (1).
Familial defective apoB100 (FDB) is a genetic disorder of LDL
metabolism characterized by hypercholesterolemia and premature atherosclerosis (4, 5). Estimated to occur in 1/500 to 1/700 people in
several Caucasian populations in North America and Europe, FDB is one
of the most common single-gene defects known to cause an inherited
abnormality (6, 7). Almost everyone with FDB is of European descent; in
most cases, the CGG-to-CAG mutation in the codon for amino acid 3500 is
on a chromosome with a rare haplotype at the apoB locus, suggesting
that most probands descended from a common ancestor who lived in Europe
about 6,750 years ago (8). The mutation substitutes glutamine for the
normally occurring arginine at position 3500 (4). Except for a few
cases in which tryptophan substitutes for arginine 3500 (9) or cysteine
for arginine 3531 (10), leading to a minor decrease in LDL receptor binding, extensive searches have not revealed any other apoB100 mutations that cause defective receptor binding of LDL (10). Both of
these mutations are located outside of the LDL receptor-binding site in
apoB100 (residues 3359-3369).
Immunoelectronmicroscopy studies have shown that the first 89% of
apoB100 enwraps the LDL particle like a belt and that the COOH-terminal
11% constitutes a bow that crosses over the belt, bringing the
COOH-terminal portion of apoB100 close to amino acid 3500 (11). It is
not certain where the carboxyl tail crosses over the belt, but the
shortest path between the epitopes for residues 4154-4189 and
4507-4513 in the three-dimensional map of apoB100 created by
Chatterton et al. (11) puts the crossover point somewhere
around residues 4275-4400. This evidence is suggestive only, as no
intervening epitopes on apoB were placed between residues 4154 and 4513 (11).
We recently reported that the COOH-terminal bow functions as a negative
modulator of receptor binding and inhibits binding of VLDL to the LDL
receptor (3). We also showed that arginine, and not simply a positive
charge, at residue 3500 is critical for normal receptor binding and
that the carboxyl terminus is necessary for the R3500Q mutation to
disrupt LDL receptor binding (3). In this study, we sought to
determine, at the molecular level, how arginine 3500 interacts with the
carboxyl terminus of apoB100.
Generation of Truncated P1 Plasmids and Isolation of DNA
Fragments for Mutagenesis--
The 95-kilobase apoB P1 plasmid p158
(12) was prepared and modified by RecA-assisted restriction
endonuclease cleavage, as described by Borén et al.
(13). A 4.7-kilobase fragment was isolated from the "apoB100
Leu-Leu" P1 plasmid with 60-mer oligonucleotides protecting the
HindIII sites at positions 43,284 and 47,951.
Site-directed Mutagenesis of P1 DNA--
The 4.7-kilobase
fragment was cloned into the pZErO vector (Invitrogen) and
subjected to site-directed mutagenesis with the ExSite PCR System
(Stratagene) with oligonucleotides "W4369Y upper" (5'
ccaagtatagttggctacacagtgaaatattatg 3') and "W4369Y lower" (5'
cataatatttcactgtgtagccaactatacttgg 3') to change tryptophan 4369 to
tyrosine. The resulting plasmids were subjected to RecA-assisted restriction endonuclease cleavage with oligonucleotides
HindIII-43284 and HindIII-47951, and the mutated
4.7-kilobase fragment was then ligated into the recipient linearized
and phosphatased apoB100 Leu-Leu P1 vector (13).
Human ApoB Transgenic Mice--
P1 DNA was prepared and
microinjected into fertilized mouse eggs (C57BL/6XSJL) (14). The two
founders with the highest levels of plasma apoB were selected for
breeding and further analysis.
Isolation of Recombinant Lipoproteins--
Recombinant LDL
(d = 1.02-1.05 g/ml) were isolated by sequential
ultracentrifugation and dialyzed against 150 mM NaCl and 0.01% EDTA, pH 7.4. Mouse apoE and apoB were removed by immunoaffinity chromatography with rabbit polyclonal antibodies against mouse apoB and
apoE (3).
Cell Culture and Receptor Binding Assays--
Competitive
receptor binding assays were performed as described by Arnold et
al. (15). The amount of unlabeled lipoproteins needed to compete
50% with 125I-labeled LDL after a 3-h incubation at
4 °C was determined from an exponential decay curve-fitting model
(15).
Immunoassays of Human Recombinant R3500Q, W4369Y, and Control
LDL--
Plate immunoassays were performed as described by Weisgraber
et al. (16), as modified by Borén et al.
(3).
Lipid Analysis of Plasma Lipoproteins--
Total cholesterol and
triglyceride levels were measured in fresh plasma samples obtained
after a 4-h fast.
Electrophoresis and Imunoblotting--
Electrophoresis was
carried out on vertical Hoefer SE 600 3-15% polyacrylamide gradient
slab gels containing sodium dodecyl sulfate (17). Each gel was run at
10 mA for 16 h at 4 °C. Separated proteins in the gels were
transferred to nitrocellulose membranes at 0.3 mA/gel for 16 h at
4 °C in a Bio-Rad Trans-Blot Cell containing 25 mM Tris, 20% methanol, 192 mM glycine, pH 8.3. Western blotting was performed with the enhanced chemiluminescense
Western blotting detection reagents (Amersham Pharmacia Biotech) as
recommended by the manufacturer; anti-human apoB monoclonal antibody
1D1 was used as the primary antibody (18).
Patients--
The patients were recruited from the
prospective Cardiovascular Risk Factors in Southern Sweden
study.2
Competitive Receptor Binding of LDL Containing Truncated Forms of
ApoB--
LDL containing carboxyl-terminally truncated forms of apoB
bind with an enhanced affinity to the LDL receptor (3, 19, 20). We
reasoned that we could identify the COOH-terminal sequence of apoB100
that interacts with the belt of apoB100 by analyzing the receptor
binding activity of LDL with different portions of the carboxyl tail
truncated. The best estimate of where the carboxyl tail crosses over
the backbone of apoB100 that enwraps the LDL particle puts the
crossover point somewhere around residues 4275-4400 (11). Therefore,
analysis of the receptor binding of LDL containing apoB-95 and apoB-97,
which are truncated at residues 4330 and 4397, respectively, should
indicate the sequence of the carboxyl tail that interacts with the apoB
backbone. Recombinant LDL containing apoB95 and apoB97, and recombinant
control LDL were isolated from human apoB transgenic mice (21), and the
endogenous apoB and apoE were removed by immunoaffinity chromatography.
The recombinant LDL contained nondegraded apoB without visible
contamination by any other protein (Fig.
1). In a competitive receptor binding assay with 125I-LDL, apoB-97 bound with the same affinity
as normal control LDL, whereas LDL containing apoB95 bound with
enhanced affinity (Fig. 2A):
the ED50 values were 1.4, 2.8, and 2.9 µg/ml,
respectively. These results indicated that an amino acid residue
between 4330 and 4397 normally interacts with arginine 3500.
Competitive Receptor Binding of Human Recombinant R3500Q, W4369Y,
and Control LDL--
We next sought to identify the residue(s) that
arginine 3500 interacts with on the carboxyl terminus of apoB100. The
finding that lysine could not substitute for arginine at residue 3500 (3) was revealing, because arginine, but not lysine, can bind to
tryptophan through a surprisingly strong cation-pi interaction (22-24). Thus, the result suggested that arginine 3500 interacts with
a tryptophan and that this interaction is critical for normal LDL
receptor binding. Of the 37 tryptophans in apoB100, only one, tryptophan 4369, is located between amino acids 4330 and 4397. Moreover, tryptophan 4369, together with arginine 3500, is conserved in
all species in which apoB has been sequenced (human, rat, pig, chicken,
and mouse) (25).
We substituted a tyrosine for tryptophan 4369 (W4369Y) and generated
transgenic mice expressing recombinant LDL. Recombinant control LDL and
LDL containing the W4369Y or R3500Q mutation were isolated from human
apoB transgenic mice. Western analysis confirmed that all endogenous
apoB and apoE had been removed by immunoaffinity purification (data not
shown). The isolated W4369Y, R3500Q, and recombinant control LDL had
identical lipid compositions (data not shown) and, as shown by negative
staining electron microscopy, had the same particle diameters as human
plasma LDL (22.3 ± 2.5, 20.3 ± 2.0, and 21.5 ± 2.7 versus 20.9 ± 3.2 nm, respectively). However, in an
in vitro competitive receptor binding assay (Fig. 2B), recombinant control LDL had receptor binding similar to
that of plasma LDL (ED50 2.3 and 1.5 µg/ml,
respectively), whereas recombinant LDL with the W4369Y mutation
displayed defective receptor binding, as did recombinant LDL with the
R3500Q mutation (3) (ED50 >20 µg/ml in both cases).
Immunoassays of Human Recombinant R3500Q, W4369Y, and Control
LDL--
The R3500Q mutation increases the affinity of the apoB
monoclonal antibody MB47 for FDB LDL (16). This antibody has a
discontinuous epitope that flanks amino acid 3500 (amino acids
3429-3453 and 3507-3523 of apoB100 (26)). To determine whether the
W4369Y mutation changes the conformation of apoB100 in the vicinity of this epitope, we isolated recombinant control LDL and recombinant LDL
containing apoB100 with the W4369Y or R3500Q mutation. In a solid-phase
radioimmunoassay (Fig. 3), MB47 had a
higher affinity for both recombinant W4369Y and R3500Q LDL
(ED50 75.1 and 74.3 ng, respectively) than for recombinant
control LDL (ED50 110.5 ng). Therefore, the loss of
arginine 3500 or tryptophan 4369 results in a conformational change and
disrupted receptor binding, two of the biochemical characteristics of
FDB.
Competitive Receptor Binding of Heterozygous R3480W LDL--
As
part of the Cardiovascular Risk Factors in Southern Sweden study,
patients with hypercholesterolemia were screened for sequence
variations in the LDL receptor and apoB genes that could affect
cholesterol plasma concentrations. Three different types of mutations
in the apoB gene were found: R3500Q, R3531C, and a previously
undescribed mutation, R3480W, in which arginine 3480 is replaced with
tryptophan. To determine the impact of this mutation on LDL receptor
binding, heterozygous R3480W LDL were isolated from a subjectively
healthy 45-year old man with mild to moderate hypercholesterolemia.
When compared with control plasma LDL in competitive receptor binding
assays, the R3480W LDL bound defectively to LDL receptors (Fig.
4). The ED50 values for human
plasma LDL and R3480W LDL were 2.2 and 8.1 µg/ml, respectively.
In this study, we investigated the molecular mechanism underlying
the interaction of arginine 3500 with the carboxyl terminus of apoB100.
Our results showed that recombinant W4369Y LDL and R3500Q FDB LDL were
equally defective in binding to LDL receptors and, perhaps more
significantly, had the same conformational change around the
receptor-binding domain, as detected by increased affinity for the
antibody MB47. The MB47 epitope lies ~850 residues away from
tryptophan 4369 (26). The observation that the W4369Y and R3500Q
mutations have the same phenotype is a powerful argument for the
importance of the R3500-W4369 interaction in facilitating the proper
conformation of apoB100 for normal receptor binding of LDL. An
interaction between arginine 3500 and tryptophan 4369 also explains why
the naturally occurring R3500W mutation causes somewhat less defective
LDL receptor binding than the R3500Q mutation (7). Tryptophan 3500 can
interact weakly with tryptophan 4369, whereas this interaction is
entirely disrupted by a glutamine at position 3500 (7).
We developed a model of how the COOH-terminal bow interacts with the
backbone of apoB100 that enwraps the LDL particle (Fig. 5). Our model predicts that arginine 3500 interacts with tryptophan 4369 and that this interaction is essential
for correct conformation of the COOH-terminal tail of apoB100. The
disruption of this interaction results in a conformational change,
disrupted receptor binding, and the clinical disorder FDB. LDL
containing apoB95 lack the carboxyl tail that crosses over the belt and
therefore have enhanced receptor binding; in contrast, apoB97 LDL
contain tryptophan 4369 and bind normally (Fig. 5). Morphological
support for the model was recently presented by Gantz et al.
(27), who showed that a proportion of sodium deoxycholate-solubilized
apoB100 LDL contained loops of a size that correlates with the
dimensions of a COOH-terminal loop stabilized by an interaction between
arginine 3500 and tryptophan 4369.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (29K):
[in a new window]
Fig. 1.
Analysis of recombinant LDL. Recombinant
LDL (d = 1.02-1.05 g/ml) from five lines of human apoB
transgenic mice were isolated by sequential ultracentrifugation and
subjected to immunoaffinity chromatography to remove endogenous mouse
apoB and apoE. A, apoB100 (5 µg) from human plasma LDL
(lane 1) or recombinant LDL (lanes 2-6) were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
on 3-15% gradient gels and visualized by Coomassie staining.
B, unpurified LDL and purified recombinant LDL (1 µg each)
were analyzed by Western blots with monoclonal antibody 1D1 against
human apoB.
View larger version (22K):
[in a new window]
Fig. 2.
Competitive receptor binding assay of
recombinant LDL. The abilities of recombinant control, apoB97, and
apoB95 LDL (A) or recombinant control, R3500Q, and W4369Y
LDL (B) to compete with 125I-labeled human
plasma LDL (2 µg/ml) for binding to LDL receptors on normal human
fibroblasts were determined. The recombinant lipoproteins were isolated
from 23 mice, and endogenous apoE and apoB were removed by affinity
chromatography. Competitor LDL were added at the indicated protein
concentrations to normal human fibroblasts, and the amount of
125I-LDL bound to the fibroblasts was measured after a 3-h
incubation at 4 °C. Human plasma LDL were included as control. Each
data point represents the mean of two independent experiments, each
performed in duplicate.
View larger version (16K):
[in a new window]
Fig. 3.
MB47 immunoassays of human recombinant
LDL. The abilities of recombinant control LDL, recombinant R3500Q
LDL, and recombinant W4369Y LDL to bind to MB47 monoclonal antibody
were determined. The recombinant LDL were isolated from 25 mice each
and analyzed in a solid-phase competitive radioimmunoassay after
removal of endogenous apoE and apoB.
View larger version (17K):
[in a new window]
Fig. 4.
Competitive receptor binding assay of R3480W
LDL. The ability of R3480W LDL to compete with normal
125I-labeled LDL (2 µg/ml) for binding to LDL receptors
on normal human fibroblasts was determined. Competitor LDL were added
at the indicated concentrations to cultures of normal human
fibroblasts. After a 3-h incubation, the amount of 125I-LDL
bound to the fibroblasts was measured. Human plasma LDL was included as
control, and plasma LDL modified with 1,2-cyclohexadione (CHD
LDL) was included as a negative control. Each data point
represents the mean of two independent experiments, each performed in
duplicate.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (72K):
[in a new window]
Fig. 5.
Model of LDL receptor binding. Normal
receptor binding in apoB100 depends on an interaction between arginine
3500 and tryptophan 4369 (R3500-W4369). Mutation of the arginine (FDB
mutation) or the tryptophan (FDB-like mutation) disrupts receptor
binding. The R3500-W4369 interaction is essential for the correct
folding of the carboxyl terminus of apoB100 to permit normal
interaction between LDL and its receptor, but this interaction is not
as favorable for receptor binding as removing the carboxyl tail. LDL
with apoB97 have normal receptor binding, whereas LDL with apoB95 lack
a carboxyl tail and therefore have enhanced receptor binding.
Tryptophan 4369 interacts not only with arginine 3500, but also with
arginine 3480 and arginine 3531. Site B (i.e. residues
3359-3369) is the receptor-binding site.
Our model further implies that tryptophan 4369 interacts with arginines in addition to arginine 3500 in apoB100 during the conversion of VLDL to LDL. Only four naturally occurring mutations in apoB100 have been unequivocally linked to defective LDL receptor binding and hypercholesterolemia: R3500Q (28), R3500W (9), R3531C (10), and R3480W (the novel mutation characterized in this study). All four mutations are located within a stretch of 51 amino acids and result in the loss of an arginine.
How does the disrupted interaction between any of these arginines and tryptophan 4369 give rise to defective LDL receptor binding? The key observation is that FDB LDL have an altered conformation in the region around the receptor-binding domain, as demonstrated by both MB47 antibody studies and 13C nuclear magnetic resonance analysis (16, 29). Furthermore, the finding that FDB LDL bind normally to proteoglycans rules out the possibility that the COOH-terminal bow interferes with the LDL receptor-binding site directly, since the principal proteoglycan-binding site of apoB100 coincides with the LDL receptor-binding site (30).
We propose that arginine-tryptophan interactions are crucial during the conversion of VLDL to LDL for positioning apoB100's carboxyl tail, which functions as a modulator element that inhibits VLDL from interacting with the LDL receptor (3), to permit apoB100 on LDL to bind normally to the receptor. A disturbed refolding process gives rise to the two characteristics of FDB: a defective conformation of apoB100 and hypercholesterolemia due to ligand-binding-defective apoB100. Interestingly, Milne and co-workers (31) recently showed that two specific regions located near the carboxyl terminus of apoB100 (between residues 4342 and 4536) and close to the LDL receptor binding site undergo a major conformational change as VLDL are converted to small LDL.
The finding that tryptophan 4369 is crucial for the correct
conformation of apoB100 is interesting in light of recent findings regarding the oxidation of tryptophans in apoB. Tryptophan oxidation has been assumed to be an early event, possibly an elementary reaction,
in the initiation of LDL oxidation (32-38). Oxidation may affect the
structure and the biological properties of the tryptophans, and it is
reasonable to speculate that oxidation of tryptophan 4369 could disrupt
the binding of LDL to its receptor.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Dr. Fred Cohen for pointing out the likelihood of an arginine-tryptophan interaction and Drs. Sven-Olof Olofsson and Stanley C. Rall for constructive discussions. We also thank K. Arnold and A. Lidell for excellent technical assistance and G. Howard and S. Ordway for editorial assistance.
![]() |
FOOTNOTES |
---|
* This work was supported by the Swedish Medical Research Council (12576, 12563, and 04966); The Swedish Foundation for Strategic Research; The Swedish Heart-Lung Foundation; Gorton's Foundation; and NHLBI, National Institutes of Health Grant HL-47660.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Wallenberg Laboratory, Sahlgrenska University Hospital, Göteborg University, S-413 45 Göteborg, Sweden. Tel.: 46-31-3422949; Fax: 46-31-823762; E-mail: jan.boren@wlab.wall.gu.se.
Published, JBC Papers in Press, December 13, 2000, DOI 10.1074/jbc.M008890200
2 U. Ekström, M. Abrahamson, L. Råstam, B. Ågren, and P. Nilsson-Ehle, submitted for publication.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: LDL, low density lipoproteins; FDB, familial defective apolipoprotein; apo, apolipoprotein; VLDL, very low density lipoproteins.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Goldstein, J. L., Brown, M. S., Anderson, R. G. W., Russell, D. W., and Schneider, W. J. (1985) Annu. Rev. Cell Biol. 1, 1-39[CrossRef] |
2. | Havel, R. J., and Kane, J. P. (1995) in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R. , Beaudet, A. L. , Sly, W. S. , and Valle, D., eds), 7th Ed., Vol. 2 , pp. 1841-1851, McGraw-Hill, New York |
3. |
Borén, J.,
Lee, I.,
Zhu, W.,
Arnold, K.,
Taylor, S.,
and Innerarity, T. L.
(1998)
J. Clin. Invest.
101,
1084-1093 |
4. | Innerarity, T. L., Weisgraber, K. H., Arnold, K. S., Mahley, R. W., Krauss, R. M., Vega, G. L., and Grundy, S. M. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 6919-6923[Abstract] |
5. | Tybjærg-Hansen, A., Gallagher, J., Vincent, J., Houlston, R., Talmud, P., Dunning, A. M., Seed, M., Hamsten, A., Humphries, S. E., and Myant, N. B. (1990) Atherosclerosis 80, 235-242[Medline] [Order article via Infotrieve] |
6. | Rauh, G., Keller, C., Schuster, H., Wolfram, G., and Zöllner, N. (1992) Clin. Invest. 70, 77-84[Medline] [Order article via Infotrieve] |
7. |
Fisher, E.,
Scharnagl, H.,
Hoffmann, M. M.,
Klusterer, K.,
Wittmann, D.,
Wieland, H.,
Gross, W.,
and März, W.
(1999)
Clin. Chem.
45,
1026-1038 |
8. | Myant, N., Forbes, S., Day, I., and Gallaghers, J. (1997) Genomics 45, 78-87[CrossRef][Medline] [Order article via Infotrieve] |
9. |
Gaffney, D.,
Reid, J. M.,
Cameron, I. M.,
Vass, K.,
Caslake, M. J.,
Shepherd, J.,
and Packard, C. J.
(1995)
Arterioscler. Thromb. Vasc. Biol.
15,
1025-1029 |
10. | Pullinger, C. R., Hennessy, L. K., Chatterton, J. E., Liu, W., Love, J. A., Mendel, C. M., Frost, P. H., Malloy, M. J., Schumaker, V. N., and Kane, J. P. (1995) J. Clin. Invest. 95, 1225-1234[Medline] [Order article via Infotrieve] |
11. | Chatterton, J. E., Phillips, M. L., Curtiss, L. K., Milne, R., Fruchart, J.-C., and Schumaker, V. N. (1995) J. Lipid Res. 36, 2027-2037[Abstract] |
12. | Linton, M. F., Farese, R. V., Jr., Chiesa, G., Grass, D. S., Chin, P., Hammer, R. E., Hobbs, H. H., and Young, S. G. (1993) J. Clin. Invest. 92, 3029-3037[Medline] [Order article via Infotrieve] |
13. | Borén, J., Lee, I., Callow, M. J., Rubin, E. M., and Innerarity, T. L. (1996) Genome Res. 6, 1123-1130[Abstract] |
14. | McCormick, S. P. A., Linton, M. F., and Young, S. G. (1994) Genet. Anal. Tech. Appl. 11, 158-164[Medline] [Order article via Infotrieve] |
15. | Arnold, K. S., Innerarity, T. L., Pitas, R. E., and Mahley, R. W. (1992) in Lipoprotein Analysis. A Practical Approach (Converse, C. A. , and Skinner, E. R., eds) , pp. 145-168, Oxford University Press, Oxford |
16. | Weisgraber, K. H., Innerarity, T. L., Newhouse, Y. M., Young, S. G., Arnold, K. S., Krauss, R. M., Vega, G. L., Grundy, S. M., and Mahley, R. W. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 9758-9762[Abstract] |
17. | Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve] |
18. | Milne, R. W., Theolis, R., Jr., Verdery, R. B., and Marcel, Y. L. (1983) Arteriosclerosis 3, 23-30[Abstract] |
19. | Parhofer, K. G., Daugherty, A., Kinoshita, M., and Schonfeld, G. (1990) J. Lipid Res. 31, 2001-2007[Abstract] |
20. | Krul, E. S., Parhofer, K. G., Barrett, P. H. R., Wagner, R. D., and Schonfeld, G. (1992) J. Lipid Res. 33, 1037-1050[Abstract] |
21. |
McCormick, S. P. A.,
Ng, J. K.,
Cham, C. M.,
Taylor, S.,
Marcovina, S. M.,
Segrest, J. P.,
Hammer, R. E.,
and Young, S. G.
(1997)
J. Biol. Chem.
272,
23616-23622 |
22. |
Gallivan, J. P.,
and Dougherty, D. A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
9459-9464 |
23. | Dougherty, D. A. (1996) Science 271, 163-168[Abstract] |
24. |
Clark, P. L.,
Liu, Z.-P.,
Zhang, J.,
and Gierasch, L. M.
(1996)
Protein Sci.
5,
1108-1117 |
25. | Segrest, J., Jones, M., Mishra, V., Pierotti, V., Young, S., Boren, J., Innerarity, T., and Dashti, N. (1998) J. Lipid Res. 3, 85-102 |
26. | Young, S. G., Koduri, R. K., Austin, R. K., Bonnet, D. J., Smith, R. S., and Curtiss, L. K. (1994) J. Lipid Res. 35, 399-407[Abstract] |
27. |
Gantz, D. L.,
Walsh, M. T.,
and Small, D. M.
(2000)
J. Lipid Res.
41,
1464-1472 |
28. | Soria, L. F., Ludwig, E. H., Clarke, H. R. G., Vega, G. L., Grundy, S. M., and McCarthy, B. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 587-591[Abstract] |
29. |
Lund-Katz, S.,
Innerarity, T. L.,
Arnold, K. S.,
Curtiss, L. K.,
and Phillips, M. C.
(1991)
J. Biol. Chem.
266,
2701-2704 |
30. |
Borén, J.,
Olin, K.,
Lee, I.,
Chait, A.,
Wight, T.,
and Innerarity, T.
(1998)
J. Clin. Invest.
101,
2658-2664 |
31. |
Wang, X.,
Pease, R.,
Bertinato, J.,
and Milne, R. W.
(2000)
Arterioscler. Thromb. Vasc. Biol.
20,
1301-1308 |
32. |
Berliner, J. A.,
Navab, M.,
Fogelman, A. M.,
Frank, J. S.,
Demer, L. L.,
Edwards, P. A.,
Watson, A. D.,
and Lusis, A. J.
(1995)
Circulation
91,
2488-2496 |
33. | Henriksen, T., Mahoney, E. M., and Steinberg, D. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 6499-6503[Abstract] |
34. | Reyftmann, J. P., Santus, R., Mazière, J. C., Morlière, P., Salmon, S., Candide, C., Mazière, C., and Haigle, J. (1990) Biochim. Biophys. Acta 1042, 159-167[Medline] [Order article via Infotrieve] |
35. | Giessauf, A., van Wickern, B., Simat, T., Steinhart, H., and Esterbauer, H. (1996) FEBS Lett. 389, 136-140[CrossRef][Medline] [Order article via Infotrieve] |
36. | Yang, C., Gu, Z., Yang, M., Lin, S., Siuzdak, G., and Smith, C. (1999) Biochemistry 38, 15903-15908[CrossRef][Medline] [Order article via Infotrieve] |
37. |
Podrez, E. A.,
Schmitt, D.,
Hoff, H. F.,
and Hazen, S. L.
(1999)
J. Clin. Invest.
103,
1547-1560 |
38. | Thomas, C. E., and Jackson, R. L. (1991) J. Pharmacol. Exp. Ther. 256, 1182-1188[Abstract] |